Viewing Study NCT02908750


Ignite Creation Date: 2025-12-24 @ 4:56 PM
Ignite Modification Date: 2025-12-25 @ 2:38 PM
Study NCT ID: NCT02908750
Status: COMPLETED
Last Update Posted: 2022-11-14
First Post: 2016-08-23
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module